Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Corominas, Josep, Sapena, Victor, Sanduzzi-Zamparelli, Marco, Millán, Cristina, Samper, Esther, Llarch, Neus, Iserte, Gemma, Torres, Ferràn, Da Fonseca, Leonardo G., Muñoz-Martínez, Sergio, Forner, Alejandro, Bruix, Jordi, Boix, Loreto, Reig, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865624/
https://www.ncbi.nlm.nih.gov/pubmed/33498698
http://dx.doi.org/10.3390/cancers13030426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865624/
https://www.ncbi.nlm.nih.gov/pubmed/33498698
http://dx.doi.org/10.3390/cancers13030426

Ejemplares similares